Rebecca A. Miksad, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Physician-Investigator at Beth Israel Deaconess Medical Center, Boston, who discussed the paper by Fine et al at the Gastrointestinal Cancers Symposium, said, “the study reports that a range of neuroendocrine tumor types responded to the capecitabine/temozolomide regimen studied. Prospective randomized, controlled data are needed to confirm these findings.” ■

Disclosure: Dr. Miksad reported no potential conflicts of interest.